| 000 | 01563 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514041143.0 | ||
| 264 | 0 | _c20030122 | |
| 008 | 200301s 0 0 eng d | ||
| 022 | _a1027-3719 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTeleman, M D | |
| 245 | 0 | 0 |
_aHepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. _h[electronic resource] |
| 260 |
_bThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _cAug 2002 |
||
| 300 |
_a699-705 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAntitubercular Agents _xadverse effects |
| 650 | 0 | 4 |
_aAspartate Aminotransferases _xblood |
| 650 | 0 | 4 |
_aBilirubin _xblood |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xepidemiology |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrazinamide _xadverse effects |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSingapore _xepidemiology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xprevention & control |
| 700 | 1 | _aChee, C B E | |
| 700 | 1 | _aEarnest, A | |
| 700 | 1 | _aWang, Y T | |
| 773 | 0 |
_tThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _gvol. 6 _gno. 8 _gp. 699-705 |
|
| 999 |
_c12037572 _d12037572 |
||